Información de Ultragenyx Pharmaceutical Inc, dividendo de Ultragenyx Pharmaceutical Inc, actividades de los accionistas y más

Más Datos de Ultragenyx Pharmaceutical Inc Compañía

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Información de Ultragenyx Pharmaceutical Inc



Símbolo de cotizaciónRARE

Nombre de la empresaUltragenyx Pharmaceutical Inc

Fecha de salida a bolsaJan 31, 2014

Director ejecutivoDr. Emil D. Kakkis, M.D., Ph.D.

Número de empleados1294

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 31

Dirección60 Leveroni Ct

CiudadNOVATO

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94949

Teléfono14154838800

Sitio Webhttps://www.ultragenyx.com/

Símbolo de cotizaciónRARE

Fecha de salida a bolsaJan 31, 2014

Director ejecutivoDr. Emil D. Kakkis, M.D., Ph.D.

Ejecutivos de Ultragenyx Pharmaceutical Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Dr. Amrit Ray, M.D.

Independent Director

18.02K

+46.74%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

15.69K

-83.00%

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Mr. Eric Olson

Chief Business Officer, Executive Vice President

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

Por negocioUSD

Nombre

Ganancia

Proporción

Crysvita royalty revenue

85.68M

51.46%

Crysvita

34.73M

20.86%

Dojolvi

23.21M

13.94%

Evkeeza

14.57M

8.75%

Mepsevii

8.31M

4.99%

Por regiónUSD

Nombre

Ganancia

Proporción

North America

102.93M

61.82%

Latin America

32.97M

19.80%

Europe

26.40M

15.86%

Japan

4.20M

2.52%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Crysvita royalty revenue

85.68M

51.46%

Crysvita

34.73M

20.86%

Dojolvi

23.21M

13.94%

Evkeeza

14.57M

8.75%

Mepsevii

8.31M

4.99%

Estadísticas de accionistas

Actualizado: vie., 15 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

10.58%

BlackRock Institutional Trust Company, N.A.

5.21%

Sands Capital Management, LLC

4.09%

T. Rowe Price Associates, Inc.

2.91%

Baker Bros. Advisors LP

2.88%

Otro

74.34%

Accionistas

Proporción

The Vanguard Group, Inc.

10.58%

BlackRock Institutional Trust Company, N.A.

5.21%

Sands Capital Management, LLC

4.09%

T. Rowe Price Associates, Inc.

2.91%

Baker Bros. Advisors LP

2.88%

Otro

74.34%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

43.48%

Investment Advisor/Hedge Fund

31.79%

Hedge Fund

20.00%

Individual Investor

3.49%

Research Firm

1.33%

Private Equity

1.31%

Sovereign Wealth Fund

1.02%

Bank and Trust

0.67%

Pension Fund

0.63%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

633

96.87M

100.52%

-1.23M

2025Q2

635

97.48M

101.32%

-2.63M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

2023Q3

574

75.90M

106.07%

-3.60M

2023Q2

591

75.05M

105.07%

-3.13M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

10.19M

10.58%

+217.20K

+2.18%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.02M

5.21%

+106.89K

+2.18%

Jun 30, 2025

Sands Capital Management, LLC

3.94M

4.09%

-220.08K

-5.29%

Jun 30, 2025

T. Rowe Price Associates, Inc.

2.80M

2.91%

-334.84K

-10.67%

Jun 30, 2025

Baker Bros. Advisors LP

2.77M

2.88%

+1.20M

+75.92%

Jun 30, 2025

Kakkis (Emil D)

2.69M

2.79%

-31.78K

-1.17%

Mar 07, 2025

JP Morgan Asset Management

2.60M

2.7%

+2.56M

+5502.04%

Jun 30, 2025

State Street Global Advisors (US)

2.57M

2.67%

-46.25K

-1.77%

Jun 30, 2025

Suvretta Capital Management, LLC

2.28M

2.36%

+253.50K

+12.52%

Jun 30, 2025

Fidelity Management & Research Company LLC

2.27M

2.36%

+1.89M

+495.36%

Jun 30, 2025

ETFs relacionados



Actualizado: lun., 6 de oct

Nombre

Proporción

Motley Fool Small-Cap Growth ETF

3.17%

Global X Genomics & Biotechnology ETF

2.93%

Franklin Genomic Advancements ETF

1.34%

Virtus LifeSci Biotech Products ETF

1.27%

WisdomTree BioRevolution Fund

0.98%

Touchstone Sands Capital US Select Growth ETF

0.8%

SPDR S&P Biotech ETF

0.59%

Goldman Sachs Future Health Care Equity ETF

0.52%

First Trust Multi-Manager Large Growth ETF

0.51%

Putnam Sustainable Future ETF

0.5%

Motley Fool Small-Cap Growth ETF

Proporción3.17%

Global X Genomics & Biotechnology ETF

Proporción2.93%

Franklin Genomic Advancements ETF

Proporción1.34%

Virtus LifeSci Biotech Products ETF

Proporción1.27%

WisdomTree BioRevolution Fund

Proporción0.98%

Touchstone Sands Capital US Select Growth ETF

Proporción0.8%

SPDR S&P Biotech ETF

Proporción0.59%

Goldman Sachs Future Health Care Equity ETF

Proporción0.52%

First Trust Multi-Manager Large Growth ETF

Proporción0.51%

Putnam Sustainable Future ETF

Proporción0.5%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos